Abstract
A biochemical response index comprising ESR, CEA and CA 15.3 was evaluated in 67 patients with systemic breast cancer treated by chemotherapy; 55 were assessable by UICC criteria and the response index (96% of all UICC assessable patients). Marker changes at 2 and 4 months showed a highly significant correlation with the UICC assessed response at 3 and 6 months (P < 0.001); sensitivity 100%, specificity 87%; positive predictive value 85%; negative predictive value 100%. This index was then used to select out truly responsive patients and to prospectively direct their chemotherapy. Twenty-six responding (biochemical/clinical) patients were randomised to discontinue cytotoxics after 6 months and move to maintenance hormones (n = 13) or continue chemotherapy whilst the biochemical markers kept falling or remained within the normal range. Biochemical progression prompted a change of chemotherapy. Continuous chemotherapy in biochemically defined responders was associated with a significant lengthening of remission duration and an improved quality of life and survival. We are now using the index to routinely direct chemotherapy and select out true responders for maintenance chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dixon, A., Jackson, L., Chan, S. et al. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?. Br J Cancer 68, 181–185 (1993). https://doi.org/10.1038/bjc.1993.310
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.310
This article is cited by
-
Fractional Tumour-Immune Model with Drug Resistance
Brazilian Journal of Physics (2024)
-
Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker
World Journal of Surgical Oncology (2010)
-
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007
Clinical and Translational Oncology (2008)
-
Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer
Journal of Cancer Research and Clinical Oncology (2008)
-
¿Cuál es la duración óptima de la quimioterapia paliativa en los pacientes con cáncer avanzado?
Revista de OncologÃa (2002)